Comparison of the RevLite Electro-optic Q-Switched Neodymium-doped Yttrium Aluminium Garnet (EO QS Nd:YAG) Laser to a Fractionated Laser System

Cynosure

Status

Completed

Conditions

Acne Scars

Photodamage

Irregular Pigmentation

Treatments

Procedure: RevLite laser treatment

Procedure: Fractionated Laser treatment

Study type

Interventional

Funder types

Industry

Identifiers

NCT00955461

C66-07-F

Details and patient eligibility

About

The purpose of this study is to compare the results of treatment between the side of the face treated with the RevLite Laser and the side of the face treated with a fractionated laser system.

Enrollment

12 patients

Sex

All

Ages

25 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Fitzpatrick Skin Type I-VI and Wrinkle Class I
Between the ages of 25-65
Evidence of bilateral dyschromia

Exclusion criteria

Pregnant, lactating, or is planning to become pregnant
history of cutaneous photosensitization, porphyria, hypersensitivity to porphyrins or photodermatosis
any skin pathology/condition that could interfere with evaluation or requires the use of interfering topical or systemic therapy
coagulation disorder or currently using anti-coagulation medication (including but not limited to heavy aspirin therapy)
any condition which, in the investigator's opinion, would make it unsafe for the subject to participate in the study
currently enrolled in an investigational drug or device trial, or has received an investigational drug or been treated with an investigational device within 30 days
unable to communicate or cooperate with the investigator due to language problems, poor mental development, or impaired cerebral function
unreliable for the study, including subjects who engage in excessive alcohol intake or drug abuse, or subjects who are unable to return for scheduled follow-up visits
Accutane within 6 months
need to be exposed to artificial tanning devices or excessive sunlight during the trial
prior treatment with parenteral gold therapy
Diabetes Type 1 or 2
does not agree to refrain from any other type of facial skin resurfacing (e.g., microdermabrasion, laser or IPL treatment, chemical peel) or injected fillers/other substances (e.g., Restylane, Botox) that might affect the treatment area for the duration of the study
artificial tanning within 1 month
(micro)dermabrasion within 3 months
other laser or IPL to the face within 6 months
chemical peel within 1 month
injectable fillers within 3 months
topical retinoids within 3 months
over-the-counter anti-aging products (e.g., those containing peptides, hyaluronic acid, or agents specifically advertised as having anti-aging or age-inhibiting properties) within 1 month
history of keloids or hypertrophic scarring
evidence of compromised wound healing
history of cold sores, chickenpox or shingles and unwilling to take a prophylactic course of Valtrex/acyclovir
allergy to acyclovir